ATL: Results of a Multi-Institutional Phase 2 Study (JGOG1066)

Toita, Takafumi; Kitagawa, Ryo; Hamano, Tetsutaro; Umayahara, Kenji; Hirashima, Yasuyuki; Aoki, Yoichi; Oguchi, Masahiko; Mikami, Mikio; Takizawa, Ken

doi:10.1097/igc.0b013e3182647265

Cited by 16 publications

(11 citation statements)

References 25 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32 Discontinuous radiation during radiochemotherapy takes place in 3-20% of the patients. [33][34][35] In the present study the interval took place in 15.7% of the patients, which is within the ranges quoted above.…”

Section: Discussion Of Resultssupporting

confidence: 69%

“…31 In the groups of patients who underwent radiochemotherapy the treatment time ranges from 35 to 92 days (average time 51-52 days). 32,33 Some researchers point out, however, that prolongation of radiochemotherapy duration, contrary to the prolongation of independent radiotherapy, does not influence the treatment results (recurrence in the radiated area, DFS, OS). 32 Discontinuous radiation during radiochemotherapy takes place in 3-20% of the patients.…”

Section: Discussion Of Resultsmentioning

confidence: 99%

“…According to the literature, 70-92% of the patients receive the planned number; in the present study 5 courses of DDP were received by 65.7% of the patients, which can be crucial for the efficiency of the treatment, since receiving fewer than 5 chemotherapy courses is related with a worse prognosis for the patients. [33][34][35][36] According to the literature the age and undergone surgery do not influence the planned course of radiochemotherapy. 34,35 Similarly, in our own research the surgery and age did not influence the interval in radiotherapy, although the age influenced the number of chemotherapy courses.…”

Section: Discussion Of Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Tolerance of combined radiochemotherapy in cervical cancer patients

Izmajłowicz¹,

Rusiecka²,

Sztuder³

et al. 2017

Adv Clin Exp Med

View full text Add to dashboard Cite

Background. Radiochemotherapy in cervical cancer was implemented to clinical practice based on 5 randomized clinical trials, published at the end of the 20 th century, which showed improvement in the total and symptomless survivals by about 10-18%. The increase of therapeutic index of such treatment can take place only when the efficiency of the treatment outweighs the increase of its toxicity. Thus, it is necessary to monitor treatment reaction during radiochemotherapy.

show abstract

Section: Discussion Of Resultssupporting

confidence: 69%

Section: Discussion Of Resultsmentioning

confidence: 99%

Section: Discussion Of Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Tolerance of combined radiochemotherapy in cervical cancer patients

Izmajłowicz¹,

Rusiecka²,

Sztuder³

et al. 2017

Adv Clin Exp Med

View full text Add to dashboard Cite

show abstract

“…In a multicenter Phase II trial, the Japanese Gynecologic Oncology Group (JGOG) study 1066 demonstrated that cisplatin-based CCRT using high-dose-rate (HDR) intracavitary brachytherapy (ICBT) achieved comparable outcomes with global dose schedules, despite Japanese centers adopting lower cumulative radiation dose schedules at Point A than those in the USA and Europe [ ]. These centers reported that HDR ICBT was feasible, with acceptable toxicity compared with previous clinical studies of cisplatin-based CCRT [ ]. However, hematologic and renal toxicities, which may lead to treatment delay or dose reduction, remained.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2–IVA cervical cancer and its clinical prognostic factors

Fujiwara

Isohashi

Mabuchi

et al. 2014

Journal of Radiation Research

View full text Add to dashboard Cite

Cisplatin-based concurrent chemoradiotherapy (CCRT) is a standard treatment for cervical cancer, but nedaplatin-based CCRT is not routinely administered. We evaluated the efficacy and safety of nedaplatin-based CCRT (35 mg/m2 weekly) and analyzed prognostic factors for survival among 52 patients with International Federation of Gynecology and Obstetrics (FIGO) Stage IB2–IVA cervical cancer treated from 1999 to 2009. Patients were treated with a combination of external beam radiotherapy of 40–56 Gy (in 20–28 fractions) and 13.6–28.8 Gy (in 2–4 fractions) of high-dose-rate (HDR) intracavitary brachytherapy or 18 Gy (in 3 fractions) of HDR interstitial brachytherapy. Overall survival (OS), progression-free survival (PFS), and local control (LC) were estimated using the Kaplan–Meier method. The Cox proportional hazard model was used for multivariate analysis. Acute and late toxicities were evaluated using the Common Terminology Criteria for Adverse Events version 4.0. The median follow-up period was 52 months. The median patient age was 63 years. The 5-year OS, PFS and LC rates were 78%, 57% and 73%, respectively. Multivariate analysis showed that histologic type, maximum tumor diameter, and pretreatment hemoglobin level were independent risk factors for PFS. Regarding adverse effects, 24 patients (46%) had acute Grade 3–4 leukopenia and 5 (10%) had late Grade 3 gastrointestinal toxicities. No patient experienced renal toxicity. Nedaplatin-based CCRT for FIGO Stage IB2–IVA cervical cancer was efficacious and safe, with no renal toxicity. Histologic type, maximum tumor diameter, and pretreatment hemoglobin level were statistically significant prognostic factors for PFS.

show abstract

“…The large tumors volume burden in addition to the advanced stage when presented plus the complication of radioresistant tumors were contributing factors to the ability to achieve effectiveness of radiation therapy. Currently, the new gold standard is concomitant chemoradiation for dealing with locally advanced cervical carcinoma (Thomas., 2000., Green et al, 2001Toita et al, 2012). In addition, The advanced sophisticated radiation techniques such as 3D conformal radiotherapy , intensity modulated radiation therapy (IMRT) along with advanced imaging applications have increased in usage for locally advanced cervival cancer (Petsuksiri et al, 2012).…”

Section: Introductionmentioning

confidence: 99%